Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
Eur Respir J
.
2019 Mar 18;53(3):1802396.
doi: 10.1183/13993003.02396-2018.
Print 2019 Mar.
Authors
Pei-Chun Chan
1
2
3
,
Pin-Hui Lee
4
,
Min-Ju Lu
4
,
You-Chieh Huang
4
,
Teng-Yi Feng
4
,
Wen-Wen Chen
5
,
Chia-Chi Lee
4
,
Yen-Fang Huang
4
,
Chen-Yuan Chiang
6
7
8
Affiliations
1
Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan pcanita.tw@cdc.gov.tw.
2
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
3
Dept of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan.
4
Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan.
5
Taiwan Drug Relief Foundation, Taipei, Taiwan.
6
Division of Pulmonary Medicine, Dept of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan.
7
Division of Pulmonary Medicine, Dept of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
8
International Union against Tuberculosis and Lung Disease, Paris, France.
PMID:
30886023
DOI:
10.1183/13993003.02396-2018
No abstract available
Publication types
Letter
Comment
MeSH terms
Aged
Antitubercular Agents
Humans
Isoniazid*
Latent Tuberculosis*
Rifampin / analogs & derivatives
Substances
Antitubercular Agents
Isoniazid
Rifampin
rifapentine